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Summary 
Context: The significant survival benefit of chemotherapy over best supportive care for 
locally advanced and metastatic NSCLC has been amply demonstrated in the literature. 
However, there is no clear evidence of the impact of the type of chemotherapy or of a 
superiority of combination chemotherapy over single-agent chemotherapy. 
Objective: The present study empirically examines, in real-life practise and using multiple 
proxies, the impact of health care expenditures on overall survival in locally advanced and 
metastatic NSCLC in order to guide medical decision-making.  
Methods: Disease characteristics, the resources used, the costs of treatment and survival data 
were retrospectively collected from the records of 175 patients treated between 2000 and 2004 
at Léon Bérard Regional Cancer Center (Lyon, France). Survival data were modelled using 
multivariate Cox models and controlled for endogeneity with the instrumental variable 
method. 
Results: The median survival for the whole cohort was 289 days. The average total cost of 
treatment reached €35,160. Survival was significantly shorter for patients with stage IV 
disease, poor performance status, and past or concomitant cardiovascular disease and/or 
diabetes, for current smokers, and for patients with adenocarcinoma compared to large cell 
carcinoma. Survival duration was not significantly associated with the total cost of treatment 
per day of hospitalisation, the number of chemotherapy drugs administered, nor inpatient 
length of stay. 
Conclusion: Higher care expenditures do not appear to improve survival for patients with 
locally advanced or metastatic NSCLC. Hence, maintaining patient quality of life and 
tailoring therapy to stage, histology and comorbidities appears to be the less bad choice. 
Key-words: Cost, NSCLC, Oncology, Survival 
JEL code: I12 -health Production; I18 - Government Policy; Regulation; Public Health 
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INTRODUCTION 
At the macro-level, increased health care expenditure implies increased benefits for the 
patients (Cremieux et al., [1999]). However, this has not yet proven true at the micro-level. 
Since the demonstration by Cochrane et al. that indicators of health care inputs are generally 
not associated with outcomes (Cochrane et al., [1978]), the failure to identify a relationship 
between health care expenditure and health outcomes has become a persistent theme in the 
literature. Socioeconomic factors are recognized to be highly associated with health outcomes 
(Nolte and Mc Kee, [2004]; Young, [2001]; Saint Leger, [2001]). Lichtenberg has shown that 
cancers for which the stock of drugs increases more rapidly tend to have greater increases in 
survival rates, and the development of new cancer drugs generally increases the life 
expectancy of people diagnosed with cancer (Lichtenberg, [2004]). Martin et al. have shown 
that health care expenditure has a strong positive effect on outcomes (Martin et al., [2007]). 
They have found that a one percent increase in expenditure per head induces, ceteris paribus, 
a 0.38% reduction in years of life lost from cancer.  
The present study focuses on the “real life" situations (as opposed to clinical trials) of patients 
with advanced or metastatic Non Small Cell Lung Cancer (NSCLC). NSCLC accounts for 
approximately 85% of all lung cancer cases, mostly late stage diseases with poor survival 
prognosis (Cella et al., [2000]; Burdett et al., [2008]). 
Indeed, patients with locally advanced NSCLC are not candidates for surgery, their median 
survival is less than one year (Galetta et al., [2002]), and their 5-year survival rate is less than 
5%. The modest survival rates, high toxicities, and high costs of treatment due to multiple 
chemotherapy regimens have prompted investigators to examine the potential benefits of new 
drugs. Clinical trials generally show that chemotherapy can improve survival, as compared to 
best supportive care, in stage IIIB and IV NSCLC (Hensing et al., [1999]; Thongprasert et al., 
[1999]; Cullen et al., [1999]; Burdett et al., [2008]; Berhoune et al., [2008]). Economic studies 
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have also shown that chemotherapy drugs are generally cost effective, as compared to best 
supportive care (Carlson et al., [2008]). However, increasing the number of chemotherapy 
prescriptions, prolonging cytotoxic therapy, and using innovative and expensive 
chemotherapy drugs do not seem to improve overall survival (Socinsky et al., [2003]; Pujol et 
al., [2005]; Rubio-Terrés et al., [2002]; Burdett et al., [2008]; Gridelli et al., [2007]).  
 
In this context, and with the objective of guiding medical decision-making, we conducted a 
real-life practice study, based on retrospective data, to analyze the effects of health care 
expenditures on survival for patients with advanced NSCLC. 
 
 
MATERIAL AND METHODS 
Inclusion and exclusion criteria 
All patients with stage IIIB or IV NSCLC treated with chemotherapy at the regional cancer 
centre of Lyon, France, between January 1, 2000 and December 31, 2004 were included in the 
study. Patients starting chemotherapy in another hospital, those receiving radiosensitizing 
chemotherapy alone, and those with stage I, II, or IIIA NSCLC were excluded from the study.  
 
Data source 
All data related to the characteristics of the patients and the resources used ( , , 
, , ) were extracted from patient records kept by the Cancer Centre. The costs of 
irradiation sessions ( ) were obtained from the “Classification Commune des Actes 
Médicaux” (CCAM), the costs of hospitalisation ( ) were calculated by the accounting 
icLOS , irLOS ,
ioLOS , imq isq ,
sc
hc
 5
department of the Cancer Centre, and the price of chemotherapy drugs ( ) was given by the 
pharmacy of the Cancer Centre. 
mp
 
Patient characteristics 
We collected data on patient age and sex, smoking habits, performance status (PS), significant 
weight loss (10% of total body weight or more), as well as disease stage (IIIB versus IV) and 
histology (adenocarcinoma versus epidermoid or malpighian carcinoma versus large cell 
carcinoma). Past or concomitant cardiovascular disease and/or diabetes were also noted. 
 
Health outcomes 
The indicator used to evaluate treatment efficacy was overall survival from the date of 
diagnosis.  
 
Cost evaluation 
Costs were calculated from the hospital’s point of view. The time horizon ranged from 
diagnosis to death (or August 2008 for living patients). Estimates were based on 2006 prices 
and costs. The total cost of treatment ( ) for patient  was defined as follows: iCT i
iiii CoCrCcCT ++=  
with , , and  the total costs of chemotherapy, radiotherapy, and other cares (e.g. 
palliative care) for patient i , defined as follows: 
iCc iCr iCo
( ) ( )hicn
m
mmi cLOSpqCc
i
i
×+×= ∑
=
,
1
 
( )hirssi cLOScqCr i ×+×= ,  
hioi cLOSCo ×= ,  
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with a chemotherapy drug administered in quantity  to patient i , and with  the unit 
price of the drug. The length of stay related to chemotherapy for patient i  ( ) covers all 
hospitalisations that included a DRG code 17M06V or 17M06W or a principal diagnosis code 
of aplasia for drugs (D61.1) or anaemia for drugs (D64.2) according to the International 
Classification of Diseases (ICD); corresponds to the daily unit cost of hospitalisation 
including expenses of staff, depreciation of equipment and building, costs of transfusions and 
drugs (except chemotherapy);  is defined as the number of irradiation sessions for patient 
, and  as the unit cost of a session including preparation. The inpatient length of stay 
related to radiotherapy for patient  ( ) covers all hospitalisations with the DRG code 
17K04Z;  covers all hospitalisations related to other care activities. To avoid a possible 
confounding
m mq mp
icLOS ,
hc
isq ,
i sc
i irLOS ,
ioLOS ,
 time effect, the total cost of treatment per day of hospitalisation for patient , 
, was assessed such as: 
i
d
iCT
ioiric
id
i LOSLOSLOS
CTCT
,,, ++
=  
We also determined the total cost of chemotherapy per cure,  such as: ciCc
ic
ic
i q
CcCc =  
where  is the number of chemotherapy cures for patient i . 
ic
q
And the total cost of radiotherapy per session:  
is
is
i q
CrCr =  
 
Proxies of health care expenditures 
Seven proxies were retained in this study, i.e. inpatient length of stay; number of outpatient 
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health care procedures; number of chemotherapy drugs administrated; number of expensive 
and innovative chemotherapy drugs administrated (i.e. reimbursed by the French National 
Health Insurance in excess of DRG tariffs), number of irradiation sessions; total cost of 
chemotherapy drugs; total cost of treatment per day of hospitalisation . diCT
 
Statistical and econometric analyses  
Descriptive statistics  
Mean and standard deviation for continuous variables, and percentage for categorical 
variables were used to analyze patient characteristics, the resources used (e.g. number of 
chemotherapy drugs administered, inpatient length of stay), and the costs of treatment. 
Survival time was calculated from the date of diagnosis until the date of death or the date of 
the last follow-up when patients were still alive (survival time was in this case therefore 
censored). Univariate survival analyses were performed by calculating Kaplan-Meier 
estimates. Differences between survival distributions were tested using log-rank statistics. 
 
Multivariate analyses  
Several expenditure indicators (logarithm of the total cost of treatment per day of 
hospitalisation, , number of chemotherapy drugs administered, inpatient length of stay), 
and survival data were modelled using multiple regression analyses. Since health care 
spendings and survival were jointly determined, expenditures were predictive of survival and 
conversely. Due to this bi-directional relationship, we could suspect a risk of endogeneity 
(Gujarati, [2005]; Greene, [2003]). Without any control for endogeneity, estimates from a 
standard Cox proportional hazard model for survival on the one hand, and from Ordinary 
Least Squares (OLS) for health expenditures models on the other hand, could be biased and 
inconsistent. Therefore we controlled endogeneity using the instrumental variable approach. 
d
iCT
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The choice of the appropriate instrument(s) was based on data from the medical literature, 
practising oncologists' expertise and on our intermediate results. For all analyses, statistical 
significance was set at 5%. Calculations were performed using Stata 10.0 software. 
 
 
RESULTS 
Descriptive statistics 
Characteristics of patients  
Main patient characteristics are described in table I. The sample consisted of a cohort of 175 
patients of whom 73% were male. Mean age at inclusion was 60 years. A vast majority of 
patients (79%) had stage IV tumours. Adenocarcinoma was the main histological group (47% 
of the patients), followed by epidermoid or malpighian carcinoma (23%), and large cell 
carcinoma (30%). In total, 124 patients were current or former smokers (71%), 21 (12%) had 
concomitant or past cardiovascular disease and/or diabetes, and 35 (20%) reported significant 
weight loss. The prevalence of poor performance status was high (63% of the patients), with 
37% of the patients scoring 2 or 3. 
 
Health outcomes 
At the time of the analysis (at least four years after diagnosis), 168 patients (96%) had died. 
The median survival for the whole cohort was 289 days (95% Confidence Interval; [230-339 
days]).  
 
Proxies of health expenditures 
Inpatient length of stay varied from 0 to 139 days. The median length of stay reached 25 days, 
with 10% of the patients staying three days or less and 90% 62 days or less. The number of 
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outpatient health care procedures varied from 0 to 87, with a median of seven. Ten percent of 
the patients never received outpatient care, whereas 90 % came for 24 visits or less. The 
number of chemotherapy drugs administered varied from 0 to 8. A majority of patients 
received between 2 and 4 drugs. Amongst the patients receiving chemotherapy, 2% did not 
receive expensive and innovative drugs, i.e. chemotherapy drugs reimbursed by the French 
National Health Insurance in excess of DRG tariffs, and a majority received one drug of the 
formulary. 76% received radiotherapy with a median number of sessions of 14 [Table II]. 
Mean cost of chemotherapy drugs reached 4,596€, ranging from 0 to 42,705€. Mean total cost 
of treatment per day of hospitalisation reached 934€, ranging from 732€ to 1,715€ [Table III]. 
 
Other costs evaluation 
The average total cost of treatment for patients with advanced or metastatic NSCLC (CT ) 
reached €35,160 (n=174), ranging from €5,602 to €131,227. The average total cost of 
chemotherapy ( cC ) reached €14,741, i.e. 42% of CT . The average total cost of radiotherapy 
( rC ) was €1,741, i.e. 5% of CT . However, as shown in table II, the average cost of 
radiotherapy for the 76 patients concerned reached €4,008. Results are detailed in table III. 
 
Univariate analysis of survival 
The median survival time was 8.0 months for men (CI 95%: [7.4; 10.0]) and 11.6 months for 
women (CI 95%: [9.6; 15.0]). The survival rate at 1 year was 36% for men and 47% for 
women. However, the overall survival of patients was not statistically different between sexes 
(p=0.06). The overall survival of patients younger than 70 years did not differ significantly 
from that of patients aged 70 and over (p=0.10). The overall survival of patients with PS ≤1 
was significantly higher than that of patients with PS >1 (p=0.0003). The median survival 
time was 11.7 months for patients with PS ≤1 (CI 95%: [8.2; 14.8]), versus 7.6 months for 
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patients with PS > 1 (CI 95%: [5.7; 9.5]). The survival rate at 1 year was 47% for patients 
with PS 1 and ≤ 25% for patients with PS> 1. The overall survival of patients was 
significantly higher for patients treated in combination with radiotherapy (p=0.04). The 
median survival time was 7.7 months (CI 95%: [6.7; 10.0]) for patients not treated with 
radiotherapy (33% survival at 12 months) and 11.6 months (CI 95%: [9.5; 15.0]) for patients 
treated (46% survival at 12 months). The Kaplan Meier survival curve stratified by stage (IIIB 
and IV) (log-rank p=0.1298) is presented in figure 1.  
 
 
Multivariate analysis of survival 
Results obtained with final survival models using instrumental variable analysis are provided 
in table IV. As mentioned above, modelling the interdependence between survival and 
expenditures may cause endogeneity problems and biased estimates. These problems could be 
overcome by using instrumental variables. The accuracy of the method relies on the relevance 
and validity of the instrumental variables available. An instrumental variable does not itself 
belong in the explanatory equation (here, does not have a direct effect on survival) for 
identification reason and must satisfy two requirements: (i) it must be strongly (or at least not 
weakly) correlated with the included endogenous variable (here, expenditures) conditional on 
the other covariates and (ii) it cannot be correlated with the error term in the explanatory 
equation (Greene, [2003]; Gujarati, [2005]). According to medical literature and to medical 
practice, age could be a valuable instrument in our context, and an age limit of 70 years would 
have clinically relevant distinctive value. Indeed, several surveys have shown that the 
intensity of cancer treatments is usually reduced for elderly patients (Gridelli et al., [2005]). 
These patients are generally more vulnerable to the toxicity of combined chemo- and radiation 
therapies, so we expected to find a negative correlation between higher age and overall 
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treatment expenditures. In contrast, age was not expected to be a predictor of survival. Even if 
there is currently no elderly-specific trial (and if elderly people are under-represented in 
clinical trials), some published studies focusing on this topic have shown that, when all 
patients receive the same treatment, progression and survival rates do not differ between 
elderly and younger patients (Sequist and Lynch, [2003]). Preliminary regressions of health 
expenditures and survival as a function of age, among other clinical variables, were ran in 
order to respectively assess the strength of this instrument in our empirical situation (cf. 
requirement 1) and whether or not the equations of interest would be identifiable.  
Our results suggested that both conditions hold when using inpatient length of stay, the 
number of chemotherapy drugs administered, and the total cost of treatment per day of 
hospitalisation as proxies of health care expenditures. Indeed, age was significantly correlated 
to each of these variables but not with survival. Unfortunately, this was not confirmed when 
using outpatient health care procedures, innovative and expensive chemotherapy drugs, the 
number of radiotherapy sessions, and the cost of chemotherapy drugs. The instrumental 
technique was not applicable to these latter cases.  
However, the assumption that the instrument (age) was not correlated with the error term in 
the equation of interest was not testable (requirement 2). In practice, in the first stage, each 
endogenous covariate (here, each expenditure indicator) was regressed (with a OLS model or 
with an ordered logistic model, Tobit type I model, or Poisson regression, according the 
nature of the variable) on all of the exogenous variables. In the second stage, the survival 
regression was estimated as usual with a Cox model, except that in this stage the endogenous 
covariate (the considered expenditure) was replaced by the predicted values from the first 
stage model while the instrument (age) was excluded from the regression. The robust option 
in Stata was used to give consistent estimates of standard errors, since this method is known 
to affect the precision of yield estimates.  
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 - Regarding the survival model as a function of inpatient length of stay, survival was, all other 
things being equal, significantly worse for patients with stage IV compared to stage IIIB 
(p=0.001), for patients with adenocarcinoma compared to large cell carcinoma (p=0.007), and 
for current smokers compared to never smokers (p=0.045). Survival duration was not 
significantly associated with inpatient length of stay (Table IV). 
 
- Regarding the survival model as a function of the number of chemotherapy drugs 
administered, survival was, all other things being equal, significantly worse for patients with 
stage IV compared to stage IIIB disease (p=0.002), for those with past or concomitant 
cardiovascular disease and/or diabetes (p=0.033), and for current smokers compared to never 
smokers (p=0.031). Survival duration was not significantly associated with the number of 
chemotherapy drugs administered (Table IV). 
 
- Regarding the survival model as a function of total cost of treatment per day of 
hospitalisation, survival time was, all other things being equal, significantly shorter for 
patients with stage IV compared to stage IIIB (p=0.003), poor performance status (p=0.006), 
and past or concomitant cardiovascular and/or diabetes co-morbidities (p=0.021). Moreover, 
current smokers had a shorter survival than never smokers (p=0.03). Survival was also 
significantly shorter for patients with adenocarcinoma compared to large cell carcinoma 
(p=0.003), whereas this significance was only borderline for weight loss (p=0.055). 
 
Our results also showed major differences in the significance and magnitude of parameters 
estimated with and without controlling for endogeneity, leading to opposite conclusions. 
Survival time was not significantly associated with the number of chemotherapy drugs 
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administrated (p=0.281) and total cost of treatment per day of hospitalisation (p=0.264) when 
using instrumental variables (this finding further confirms the validity of our instrument), as 
was the case when the original variables were used (p=0.004 and p<0.001, respectively). These 
results confirmed our initial suspicion that seriously biased results were obtained when 
dealing with health expenditures variables, due to reciprocal causation between cost and 
survival (Table IV). 
 
 
DISCUSSION 
Choice of the health care expenditure proxies 
Hospitalisation is described in the literature as the most expensive cost item for advanced and 
metastatic NSCLC (Bordeleau, [2006]). In Dedes et al. study, hospitalisation costs reach 68% 
and 74% of the total costs of treatment in stage III and stage IV patients, respectively, versus 
only 14% and 26% for chemotherapy drugs (Dedes et al., [2004]). Health care expenditures 
related to hospitalisation are largely integrated in our analysis, e.g. inpatient length of stay, 
number of outpatient health care procedures, total cost of treatment per day of hospitalisation. 
Health care expenditures related to chemotherapy drugs are also detailed, e.g. number of 
chemotherapy drugs administered, number of expensive and innovative chemotherapy drugs 
administered, total cost of chemotherapy drugs). As radiotherapy can palliate the symptoms of 
poor-prognosis patients, the number of irradiation sessions was also taken into account (Van 
den Hout et al., [2006]).  
Because this is a retrospective study, rigorously assessing quality of life was not possible. The 
literature shows low quality of life scores in patients with locally advanced and metastatic 
NSCLC. Bordeleau reports a score of 0.34 (Bordeleau, [2006]). Van den Hout et al. report a 
total of 10% of negative utility measurements, indicating a health state worse than death in 
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palliative NCSLC. However, toxicities (e.g. febrile neutropenia, diarrhoea, nausea and 
vomiting) could be introduced in order to reinforce the present analysis. 
 
A real-life practise study of health care expenditures and survival 
The effect of health care expenditures on survival in locally advanced and metastatic NSCLC 
was assessed in a real life situation with no previous selection of the patients, contrary to 
clinical trials. Hence, non surprisingly, the survival results obtained are worse than those of 
six clinical trials identified by a literature search of Medline for stage IIIB and IV NSCLC 
since 2000 (Babiak et al., [2007]; Chen et al., [2002]; Galetta et al., [2002]; Perry et al., 
[2007]; Pujol et al., [2005]; Zinner et al., [2004]). The periods of inclusion of those clinical 
trials ranged from 1998 to 2001, except for the study reported by A. Babiak et al. which ran 
from 2002 to 2005 (Babiak et al., [2007]). Except for this study, the median survival reported 
in clinical trials was higher than in our study. It ranged from 10.5 months (Galetta et al., 
[2002]) to 17.4 months (Zinner et al., [2004]), compared to 9.6 months in this study.  
 
The necessity to analyse the risk of endogeneity  
Gravelle and Backhouse have highlighted the methodological difficulties associated with 
empirical investigations in health care, especially the associated endogeneity problem, and the 
possible time lag between expenditure and outcomes (Gravelle and Backhouse, [1987]). 
When the estimated regression equation consists of a mixture of potentially endogenous and 
exogenous variables, the coefficient on the endogenous variables may be biased when studies 
do not allow for endogeneity (Martin et al, [2008]). The risk of endogeneity and its impact on 
the relationship between health care expenditures and outcome appear clearly in this study. 
When endogeneity is not taken into account, the higher the total cost of treatment per day of 
hospitalisation, the higher the survival rate, and the higher the number of chemotherapy drugs 
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administrated, the higher the survival rate. This would lead to the conclusion that health care 
expenditures have a strong positive effect on survival in patients with advanced or metastatic 
NSCLC, which would bias the decision-making process in favour of expensive therapies.  
 
Results homogenous with the literature in term of benefit regarding health care 
expenditures 
Survival time was not significantly associated with either total daily cost or the number of 
chemotherapy drugs administered and inpatient length of stay. These results reinforce the 
literature which shows that increasing the number of chemotherapy prescriptions, prolonging 
cytotoxic therapy, and using innovative and expensive chemotherapy drugs do not 
significantly improve survival in locally advanced and metastatic NSCLC (Rubio et al., 
[2002]; Socinsky et al., [2003]). Our results are also in agreement with those of a meta-
analysis of 16 trials, which has failed to provide clear evidence of a difference in the effect of 
chemotherapy between different chemotherapy types or between trials that used combination 
chemotherapy and those that used single agent chemotherapy (Burdett et al., [2008]).  
 
Implications in term of medical decision-making 
Due to the short survival times observed in advanced or metastatic NSCLC, especially in the 
“real life situation”, to the lack of consequences of health care expenditures on survival as 
measured by seven proxies, but also, as shown in the literature, to the significant benefit of 
chemotherapy on survival, the elaboration of recommendations for medical decision-making 
appears particularly difficult. The American Society for Clinical Oncology recommends, for 
example, the administration of a combination of two molecules of chemotherapy in first-line, 
whereas brief cyto-toxic treatments also appear optimal. Further studies encourage to 
maintain quality of life and to tailor therapy to patient characteristics and disease specificities 
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(age, stage, histology and comorbidities). Based on the present study, we recommend not to 
multiply chemotherapy drugs and to encourage the use of less expensive drugs. This is 
particularly important within the French health care system because: (i) Expensive and 
innovative drugs are reimbursed to the hospitals by the national health insurance in excess of 
DRG tariffs, while the costs of other chemotherapy drugs are supported by the hospital as part 
of the DRG. (ii) Clinical phase IV trials are generally not performed. (iii) Cost effectiveness 
acceptability curves and willingness to pay thresholds are not specified by the French 
National insurance system. 
 
 
CONCLUSION 
Although there has been progress in the treatment of NSCLC, survival is still very modest for 
advanced and metastatic stages. In term of medical-decision making, the present study based 
on a “real life situation”, using several proxies of health care expenditures and controlling the 
risk for endogeneity, encourages to limit the number of chemotherapy drugs administered and 
to promote the use of inexpensive drugs. This study also shows the importance of tailoring 
cytotoxic therapy based, according to the results of survival models, on age, stage, histology 
and comorbidities. Then, the focus of research on medical decision-making should be on (i) 
the observation of physicians' behaviour, in particular the reasons why they prescribe non 
efficient drugs (ii) the preservation of quality of life, based on the results of evaluations of 
targeted therapies which are pending in lung cancer (Bordeleau, [2006]; Glover et al., [2004]). 
The mean estimated annual cost of targeted drugs may however reach $21,963 for Gefitinib, 
$31,000 for Erlotinib. As targeted cancer drugs are combined with standard regimens, the 
costs of these drugs add to already costly therapeutic packages. Hence, high-quality 
evaluations are required to provide clear information on the value and the acceptability of the 
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costs of those treatments. Hopefully, targeted therapy could become a favourable option, and 
a societally viable solution, in advanced and metastatic NSCLC. 
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 Table I 
Distribution of sociodemographic factors, smoking status and clinicopathologic 
variables (n=175 patients) 
 
Characteristics Mean ±SD or number of 
patients (%) 
Age (years)  59.8± 10.8 
Male / Female  128 (73%) / 47(27%) 
Tumor stage  
IIIb 37 (21%) 
IV 138 (79%) 
Histology   
Adenocarcinoma 82 (47%) 
Epidermoid or malpighian carcinoma  41 (23%) 
Large cell carcinoma 52 (30%) 
Performance status   
0 5 (3%) 
1 106 (60%) 
2 52 (30%) 
3 12 (7%)  
Smoking status  
Never 51 (29%) 
Former 42 (24%) 
Current 82 (47%) 
 25
Weight loss  
Yes 35 (20%) 
No 140 (80%) 
Past or concomitant cardiovascular disease 
and/or  diabetes 
 
Yes 21(12%) 
No 154(88%) 
Survival status  
Dead  168 (96%) 
Alive 7 (4%) 
(a) 8 missing data 
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Table II 
Main resources used 
 
Main resources used N° of patient (%) 
Number of drug administrated   
One drug administrated 14 (8.0%) 
Two drugs administrated 60 (34.3%) 
Three drugs administrated 43 (24.6%) 
Four drugs administrated 35 (20.0%) 
Five or more 23 (13.1%) 
Median [min-max] 3 [1-8] 
Number of expensive and innovative chemotherapy 
drugs  
 
None drug of the list 5 (2.9%) 
One drug of the list 76 (43.4%) 
Two drugs of the list 54 (30.9%) 
Three  drugs of the list 30 (17.1%) 
Four drugs of the list 5 (2.9%) 
Five drugs of the list 5 (2.9%) 
Median [min-max] 2 [0-5] 
Inpatient length of stay   
Mean (± standard deviation) 29.0 (±26.1) 
Median [min-max] 25 [0-139] 
Number of outpatient health care procedures  
Mean (± standard deviation) 10.7 (±11.6) 
 27
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Median [min-max] 8 [0-87] 
Number of radiotherapy session administrated (1)  
None  99 (56.6%) 
Median(1) [min-max] 14 [1-37] 
 
 
 
 
Table III 
Average costs (in €) 
 
 Costs including zero values  Costs excluding zero values 
 n Mean (SD) Range n Mean (SD) Range 
Total cost of treatment  174 35,160 (24,222) 5,602 - 131,227     
Total cost of treatment per day of hospitalisation 174 934 (220) 732 - 1,715     
Total cost of chemotherapy 174 14,741 (14,442) 8 - 113,668     
          Cost of chemotherapy drugs 174 4,596 (5,880) 8 - 42,705     
          Cost of hospitalisations for chemotherapy 174 10,145 (9,477) 0 - 70,963 162 10,901 (9,391)  732-70,963
Total cost of chemotherapy per cure 174 1,750 (1,367) 8 – 9,445     
Total cost of radiotherapy 175 1,741 (3,274) 0 - 22,428 76 4,008 (3,958) 491 - 22427 
          Cost of sessions 175 1,340 (2,076) 0 - 9,695 76 3,085 (2,131) 491 – 9695 
          Cost of hospitalisations for radiotherapy 175 401 (2,219) 0 - 19,753 10 7,023 (6,600) 732 – 19752 
Total cost of radiotherapy per session 175 117 (204) 0 - 1,495 76 270 (235) 162 - 1,495 
Total other costs 175 18,611 (18,098) 0 – 93,642 167 19,503 (18,051) 732 – 93,642 
 
 
 
Table IV 
Results of the final survival model as a function of sociodemographic factors, smoking status and clinicopathologic variables, and Health 
expenditure with and without controlling for endogeneity (n=173) 
 
Health expenditure Total cost of treatment per day 
of hospitalisation (log) 
 Number of chemotherapy drugs 
administrated 
 Inpatient length of stay 
 Controlling for endogeneity  Controlling for endogeneity  Controlling for endogeneity 
 Yes No  Yes No  Yes No 
 Hazard 
ratio 
P>|t| Hazard 
ratio 
P>|t|  Hazard 
ratio 
P>|t| Hazard 
ratio 
P>|t|  Hazard 
ratio 
P>|t| Hazard 
ratio 
P>|t| 
Female (ref: male) 1.04281 0.839 1.01037 0.947  0.93049 0.704 0.9691 0.864  0.91382 0.639 0.91582 0.663 
Stage IV (ref : stage IIIb) 2.15469 0.002 1.48355 0.083  1.83130 0.002 1.91752 0.002  1.89524 0.001 1.95180 0.003 
Adenocarcinoma (ref: large cell) 0.52881 0.003 0.64398 0.020  0.63043 0.055 0.61535 0.028  0.56845 0.007 0.52120 0.001 
Epidermoid/malpighian (ref: large 
cell) 
1.01035 0.954 1.09182 0.697  1.02431 0.917 1.04670 0.851  1.02322 0.920 1.02248 0.920 
Performance status>1 (ref: 1 or 
less) 
1.37768 0.006 1.42885 0.003  1.19023 0.358 1.21532 0.124  1.22927 0.216 1.35113 0.012 
 
 
 
 
Current smoker (ref: never) 1.55127 0.030 1.66234 0.015  1.54897 0.031 1.46691 0.054  1.51516 0.045 1.56880 0.029 
Former smoker (ref: never) 1.16595 0.527 1.40401 0.185  1.16195 0.537 1.18953 0.434  1.07158 0.802 1.12446 0.644 
Weight loss (1=yes, 0=no) 1.62077 0.055 1.16654 0.462  1.35984 0.214 1.32998 0.262  1.50677 0.086 1.55415 0.036 
Co-morbidities (1=yes, 0=no) 1.86777 0.021 1.54567 0.088  1.70429 0.033 1.67673 0.047  1.54115 0.090 1.61693 0.058 
Health expenditure 8.80018 0.264 0.15447 0.000  0.59444 0.281 0.84212 0.004  0.98594 0.281 0.99481 0.053 
Schoenfeld tests of the proportional 
hazards hypothesis 
p= 0.9972 p= 0.9415  p=0.9964 p=0.2216  p=0.9964 p=0.8753 
 
 
 
 
 Figure 1 
Kaplan-Meier survival curve stratified by stage 
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